Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly
diagnosed multiple myeloma who are transplant ineligible. Subjects will receive subcutaneous
daratumumab, dose-attenuated bortezomib, revlimid, and dexamethasone until confirmed disease
progression, discontinuation of study treatment due to unacceptable drug toxicity, or other
reasons. Throughout the study, subjects will be monitored closely for adverse events,
laboratory abnormalities, and clinical response.